Alpha Nuclide's Research & Manufacturing Capabilities to Unlock Access to China Market, Targeting Clinical Trials for NY-703 in HCC in 2026

MIAMI, 2654 / ACCESS Newswire / October 13, 2025 / MIAMI, FL and JIAXING, CHINA / ACCESS Newswire / October 13, 2025 / NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies today announced it has entered into a research & manufacturing partnership agreement with Alpha Nuclide, a radiopharmaceutical solutions company pioneering the global ²¹¹At supply, CRO, and CDMO services.

"We are excited to partner with Alpha Nuclide, a leader in Astatine-211 research and manufacturing. Their growing facilities and deep understanding of the precision manufacturing and supply chain logistics for Astatine-211 makes them an ideal partner for advancing our programs." commented NAYA CEO Dr. Daniel Teper. "Access to the China market and its large HCC population is critical to accelerating initial data readouts for NY-703 prior to expanding development to patients in the US and Europe. We see Alpha Nuclide's supply chain solutions in China as a validating model for future global expansion of Astatine-211 radiopharmaceuticals."

"We see the collaboration with NAYA Therapeutics as an important step towards accelerating the development of Astatine-211 targeted alpha therapies," added Dr. Yutian Feng, CEO of Alpha Nuclide. "Astatine-211 is increasingly recognized as an optimal, "goldilocks" alpha-particle emitter with highly-attractive properties including a short half-life, clean decay, minimal toxicity, and potential for broad supply, overcoming the limitations over other radionuclides and unlocking the potential of alpha therapies to address the needs of cancer patients at risk of residual disease & metastasis"

Under the agreement, Alpha Nuclide will supply ²¹¹At to NAYA Therapeutics, which is produced at its East China production center near Shanghai where the first-of-its-kind TR-Alpha cyclotron was installed in the state-of-the-art facility. The agreement underscores Alpha Nuclide's strategic mission to make ²¹¹At accessible for radiopharmaceutical innovators globally. By combining secure supply with a one-stop CDMO service model, Alpha Nuclide is building the ecosystem necessary for ²¹¹At programs to move from discovery into clinical and commercial reality. By initiating a second facility in Shijiazhuang City near Beijing, Alpha Nuclide continues to build its fully integrated targeted alpha therapy (TAT) infrastructure.

The partnership will also support 2026 investigator-initiated clinical trials in China for NY-703, NAYA's GPC3-targeting ²¹¹At alpha therapy for the treatment of residual disease & metastasis in hepatocellular carcinoma (HCC). China has a particularly large local HCC population, with over 200,000 new cases annually. The partnership would also enable an option to scale patient recruitment as part of a global development plan.

The Alpha Nuclide collaboration follows two other recent partnerships with Ionetix and Atley Solutions as NAYA tightly knits together the critical components to consolidate the establishment of a decentralized ²¹¹At supply network and sustain its early mover advantage.

About NY-703

NY-703 is a GPC3-targeting Astatine-211 (²¹¹At) targeted alpha therapy for the treatment of residual disease & metastasis in hepatocellular carcinoma (HCC), aiming to achieve initial clinical data in 2026. It consists of a GPC3-antibody fragment F(ab')2 conjugated to an Astatine-211 isotope. HCC is a rapidly-growing cancer with an estimated one million new patients every year. Up to 75% of HCC patients treated with surgery and/or immunotherapy relapse within 5 years, often due to the presence of metastases and minimal residual disease (MRD).

About NAYA Therapeutics

NAYA Therapeutics is pioneering the next generation of cancer therapies, aiming to unlock deeper, more durable responses in patients not responding to current standard-of-care. NAYA's pipeline harnesses the transformational potential of two synergistic modalities: Astatine-211 (²¹¹At) targeted alpha therapies & NK cell engaging bifunctional antibodies, with an initial focus on hepatocellular carcinoma (HCC). For more information, please visit www.nayatx.com.

About Alpha Nuclide

Alpha Nuclide is a leading supplier of Astatine-211, one of the most promising alpha-particle emitting radionuclides, and provides radiopharmaceutical manufacturing services in China. With core expertise in cyclotron-based production, TAT drug discovery services, GMP compliance, and clinical logistics, Alpha Nuclide supports biopharma partners from early-stage research through commercial supply. The company enables efficient, reliable delivery of short-lived isotopes for next-generation TATs.

NAYA Media & Investor Contact

Lyn Falconio, Chief Communications Officer
917-575-1844
lyn@nayatx.com

Alpha Nuclide Media & Investor Contact

Weibin Zhuo, Co-Founder and CFO
+86 13586815088
weibin.zhuo@astathera.com

SOURCE: NAYA Therapeutics